

References

1. **Abedlrahman, A . and Pang C.C. Y. (1992):** Competitive antagonism of pressor responses to angiotensin III by the angiotensin II-I receptor ligand losartan. *Can. J. Physiol. Pharmacol.*, 70: 716-719.
2. **Ahmad, S. (1997):** Angiotensin receptor antagonist delay nitric oxide-deficient stroke in stroke prone rats. *Eur J. Pharmacol.*, 333: 39-45.
3. **Alfoldi, S. (2003):** Diurnal blood pressure control in the optimal treatment of hypertension. *Orv. Hetil.*, May 4;144 (18 Suppl 1):895-897.
4. **Allen, A.M.; Zhuo, J. and Mendelsohn F. (2000) :** Localization and function of angiotensin AT₁ receptors. *Am. J. Hypertens.*, 13: 31S-38S.
5. **Amerena, J.; Pappas, S.; Ouellet, J.P.; Williams, L. and O'Shaughnessy, D. (2002):** ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. *J. Int. Med. Res.*, Nov-Dec;30(6):543-552.
6. **Andersen, S.; Jacobsen, P.; Tarnow, L.; Rossing, P.; Juhl, T.R. and Parving, H.H. (2003):** Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. *Nephrol. Dial. Transplant.* Feb;18(2):293-297.
7. **Asmar, R.; Gosse, P.; Topouchian, J.; N'tela, G.; Dudley, A. and Shepherd GL.(2002):** Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. *J. Renin Angiotensin Aldosterone Syst* Sep;3(3):176-180.
8. **Bakris, G. (2002):** Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. *J. Clin. Hypertens. (Greenwich)* Jul-Aug;4(4 Suppl 1):26-31.
9. **Balt, J.C.; Mathy, M.J.; Pfaffendorf, M. and van Zwieten, P.A. (2002):** Sympatho-inhibitory properties of various AT₁ receptor antagonists. *J. Hypertens.*; 20 Suppl 5:S3-11.

10. **Bao, G.; Gohlke, P.; Qadri, F.; et al. (1992):** Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. *Hypertension*; 20:74-79.
11. **Bauer, J.H. and Rames, G.P. (1995):** The angiotensin II type I receptor antagonists. A new class of antihypertensive drugs. *Arch. Intern. Med.* 155 (13): 1361-8.
12. **Beevers, D.G. (1995):** Losartan: the first angiotensin receptor antagonist in clinical use. *J Hum Hypertens.* 9 Suppl 5:S1.
13. **Bergstrom, G.; Johansson, I. Wickman, A.; Gan, L. and Thorup, C. (2002):** Brief losartan treatment in young spontaneously hypertensive rats abates long-term blood pressure elevation by effects on renal vascular structure. *J. Hypertens.* ; 20(7): 1413-1421.
14. **Berk, B.C. and Corson, M.A. (1997):** Angiotensin II signal transduction in vascular smooth muscle. Role of tyrosine kinases. *Circ. Res.* 80: 607-616.
15. **Berry, C.; Touyz, R.M.; Dominiczak, F. ; Webb, R. C. and Johns, D. G. (2001):** Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide *Am. J. Physiol. Heart Circ. Physiol.* Dec. 281: H2337-H2365.
16. **Boffa, J.J.; Lu, Y.; Placier, S.; Stefanski, A.; Dussaule, J.C. and Chatziantoniou C. (2003):** Regression of Renal Vascular and Glomerular Fibrosis: Role of Angiotensin II Receptor Antagonism and Matrix Metalloproteinases *J. Am. Soc. Nephrol.* 14(5):1132-44.
17. **Bohm, M.; Lee, M.; Kreutz, R.; Kim, S.; Schinke, M.; Djavidani, B.; Wagner, J.; Kaling, M.; Wienen, W. and Bader, M. (1995):** Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. *J. Hypertens.* Aug;13(8):891-899.
18. **Bohm, M.; Lippoldt, A.; Wienen, W.; Ganten, D. and Bader, M. (1996):** Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor Blockade. *Mol. Cell Biochem.* Oct-Nov;163-164:217-221.

19. **Bouaziz, H.; Joulin, Y.; Safar, M. et al.(1994):** Effects of bradykinin B₂ receptor antagonism on the hypotensive effects of ACE inhibition. *Br. J. Pharmacol.*;113:717-722.
20. **Bovy, P.R., and Olins, G.M. (1992):** Recent advances in nonpeptidic angiotensin II receptor antagonists: Current Drugs: Renin angiotensin system London: Current Patents Ltd., Middlesex. House.
21. **Brush, J.E.; Cannon, R.O.; Schenke, W.H.; Bonow, R.O.; Leon, M.B.; Maron, B.J. and Epstein, S.E. (1988):** Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. *N. Engl. J. Med.*;319:1302-1307.
22. **Bunnenmann, B.; Fuxe, K. and Ganten, D. (1993):** The rennin-angiotensin system in the brain : an update 1993. *Regul . Pept.* 46:487-509.
23. **Burgess, E.D. and Buckley, S. (2000):** Long term effect of telmisartan on sodium excretion in hypertensive patients. *Can J. Cardiol* Sep. 16 Suppl. F: 106F.
24. **Burn, J.H. (1952):** Practical pharmacology. Blackwell Scientific Publications; P35-37.
25. **Burnier, M. (2001):** Angiotensin II Type 1 Receptor Blockers. *Circulation.*; 103(6): 904 - 912.
26. **Burnier, M. and Maillard, M. (2001):** The comparative pharmacology of angiotensin II receptor antagonists. *Blood Press*;10 Suppl 1:6-11.
27. **Burnier, M.; Rtschmann, B. and Nussberger, J, (1993):** Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. *Hypertension* 22: 339-347.
28. **Campell, L.J. and Habener, J.E (1986):** Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. *J.Cli Invest*; 78: 31-39.
29. **Carey, R.M.; Mangrum, A. and Siragy, H.M. (1999):** Angiotensin (ANG) II induced hypotension and increased renal guanosine

- cyclic 3',5'-monophosphate (cGMP) in mice lacking the subtype-1A (AT_{1A}) ANG receptor (Abstract). *Hypertension*; 34: 141.
30. Carey, R.M.; Wang, Z.Q. and Siragy, H. (2000): Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. *Hypertension*; 35: 155-163.
 31. Carswell, C.I. and Goa, K.L. (2003): Losartan in diabetic nephropathy. *Drugs*; 63(4):407-14; discussion 415-416.
 32. Chamorro, V.; Wangenstein, R.; Sainz, J.; Duarte, J.; O'Valle, F.; Osuna, A. and Vargas, F. (2003): Protective effects of AT₁ receptor blockade in low-renin DOCA-treated spontaneously hypertensive rats. *Clin. Sci. (Lond)*. Oct 2 [Epub ahead of print].
 33. Chen, H.H.; Redfield, M.M.; Nordstrom, L.J.; Cataliotti, A. and Burnett, J.C. (2003): Angiotensin II AT₁ receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. *Am. J. Physiol. Renal Physiol.*; May; 284(5):F1115-9.
 34. Chiu, A.T.; Mc Call, D.E. and ardecky, R.J. (1990a): Angiotensin II receptor subtypes and their selective non peptide ligands. *Receptor* 1: 33-40.
 35. Chiu, A.T.; Mc Call, D.E/ and Price W.A. (1990b): Nonpeptide angiotensin II antagonists. Cellular and biochemical pharmacology of DuP 735, an orally active antihypertensive agent. *J. Pharmacol. Exp. Ther.*; 525: 711-18.
 36. Chiu, A.T.; Mc Call, D.E. and ardecky R.J. (1990c): [³H] DuP 753, a highly potent and specific and radioligand for the angiotensin II-I receptor subtype. *Biochem. Biophys. Res. Commun.*; 172:1195-202.
 37. Chiu, A.I: Mc Call, D.E and Price W.A. (1991): In vitro pharmacology of DuP 753. *Am. J. Hypertens.*; 4Suppl: 282S-7S.
 38. Chowta KN, Chowta MN, Bhat P, Adhikari PM. (2002): An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. *J. Assoc. Physicians India.*; 50:1236-9.

39. Christ, D.D (1995): Human plasma protein binding of the angiotensin II antagonist losartan potassium (DuP753/MK 954) and its pharmacologically active metabolite EXP 3147. *J. Clin. Pharmacol.*; 35: 515-20.
40. Christ, D.D.; Kilkson, T.; Wong, N.; et al (1990): Formation and deposition of EXP 3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist DuP 753 in : Program and abstract of the International Society for the study of Xenobiotica (ISSX); October 21-25; San Diego, Calif. Abstract 137.
41. Clauser, E.; Gaillard, I.; Wei, L.; and Corvol, P. (1989): Regulation of angiotensin gene. *Am J. Hypertens*; 2: 403-410.
42. Crawford, D.C.; Chobanian, A.V. and Brecher, P. (1994): Angiotensin II induces fibronectin expression associated with cardiac fibrosis in rat. *Circ. Res.* 74: 727-739.
43. Criscione, L.; De Gaspro, M.; Busehlmayez, P.; White bread, S.; Ramjoue, H.P. and Wood, J.M. (1992): Pharmacological profile of C.G.P. 48933, a novel non peptide antagonist of AT₁ receptor. *J. Hypertens. (G.B.)* 10, suppl. 4, 196.
44. Culman, J.; von Heyer, C.; Piepenburg, B.; Rascher, W. and Unger, T. (1999): Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. *Eur. J. Pharmacol* 367: 255-265.
45. Cupisti, A.; Rizza, G.M.; D'Alessandro, C.; Morelli, E. and Barsotti, G. (2003): Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. *Biomed. Pharmacother.*; May-Jun; 57 (3-4): 169-72.
46. Danser, A.H. (1996): Local renin-angiotensin systems. *Mol. Cell Biochem.* 157: 211-216.
47. De Chaffoy de Courcelles, D.; Leysen, Roevens, P. and Van Belle, H. (1986): The serotonin S-2 receptor: a receptor-transducer coupling model to explain insurmountable effects. *Drug Dev. Res.* 8: 173-178.

48. **De Gasparo, M, Catt KJ, Inagami T, Wright JW, and Unger T. (2000):** International Union of Pharmacology XXIII: the angiotensin II receptors. *Pharmacol Rev* 52: 415-472.
49. **Desarnaud, F.; Marie, J.; Lombard, C.; Languier, R.; Seyer, R.; Lorca, T.; Jard, S. and Bonnafous, J.C; (1993):** Deglycosylation and fragmentation of purified rat liver angiotensin II receptor: Application to the mapping of hormone-binding domains. *Biochem. J.* 289: 289-297.
50. **Dhalla, N.S ; Xu ,Y.J.; Sheu,S.S Tappia, P.S. and Panagia, V. (1997):** Phosphatidic acid: A potential signal transducer for cardiac hypertrophy. *J Mol Cell Cardiol* 29: 2865-2871.
51. **DiSalvo, J. and Fell, C. (1970):** Effect of angiotensin on canine renal blood flow. *Proc.Soc.Exp.Biol.(N.Y.)* 133:1432.
52. **Doig, J.K.; MacFadyen, R.J. and Sweet, C.s. (1993):** Dose ranging study of the angiotensin type I receptor antagonist losartan (Dup 753/ MK 954), in salt-deplete normal man. *J. Cardiovasc. Pharmacol.* 21: 732-8.
53. **Donmez, G.; Derici, U.; Erbas, D.; Arinsoy, T.; Onk, A.; Sindel, S.; Hasanoglu, E. (2002):** The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. *Jpn. J. Physiol.* Oct;52(5):435-40.
54. **Drimal, J. (1968):** effect of angiotensin II on coronary smooth muscle. *Eur. J. Pharmacol.* 5: 56.
55. **Dubois, M. and Wilson, T.W. (1997):** A new antihypertensive drug. Losartan. *Can. Nurs.* 93 (6): 31-34.
56. **Dulin, N.O.; Alexander, L.D.; Harrwalkar, S.; Falck, J.r. and Douglas, J.G. (1998):** Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. *Proc. Natl. Acad. Sci. USA.* 95: 8098-8102
57. **Dunselman, P.H. Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators. (2001):** Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in

- patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. *Int. J. Cardiol.* Feb;77(2-3):131-8; discussion 139-40.
58. Dzau VJ (1989): Multiple pathways of angiotensin production in the blood vessel wall: Evidence, possibilities and hypotheses. *J. Hypertens.* 7: 933-936.
59. Dzau, V.J; Ingelfinger, J.R. and Pratt, R.E. (1986): Regulation of tissue renin and angiotensin gene expression. *J. Cardiovasc. Pharmacol.* 8 (Suppl. 10): S11- S16.
60. Ebner, T., and Roth, W. (1999): In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist, [abstract no. P.47 and poster]. *J. Hum. Hypertens.* May; 13 Suppl. 3: S13.
61. Ebner, T.; Heinzl, G.; Prox, A.; Beschke, K. and Wachsmuth, H. (1999): Disposition and chemical stability of telmisartan 1-O-acetylglucuronide. *Drug Metab. Dispos.* Oct;27(10):1143-9
62. Esther, C.R.; Marino, E.M. and Howard, T.E. (1997): The critical role of tissue angiotensin-converting enzymes as revealed by gene targeting in mice. *J. Clin. Invest.* 99: 2375-2385.
63. Fernandez-Vega, F.; Abellan, J.; Sanz de Castro, S.; Cucalon, J.M.; Maceira, B. and Gomez de la Camara, A. (2001): A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. *Int. Urol. Nephrol.*;32(4):519-23.
64. Ferrario, C.M.; Chappell, M.C.; Tallant, E.A.; Brosnihan, K.B. and Diz, D.I. (1997): Counterregulatory actions of angiotensin (1-7). *Hypertension* 30: 535-541.
65. Fierens, F.L.P.; Vanderheyden, P.M.L.; de Backer, J.P. and Vauquelin, G. (1999): Binding of the antagonist [³H]candesartan to angiotensin II AT1 receptor-transfected Chinese hamster ovary cells. *Eur. J. Pharmacol.* 367: 413-422.
66. Folkow, B. (1982): Physiological aspects of primary hypertension. *Physiol. Rev.*;62:347-504.

-
67. Fortepiani LA, Ruiz MC, Passardi F, Bentley MD, Garcia-Estan J, Ritman EL, Romero JC. (2003): Effect of losartan on renal microvasculature during chronic inhibition of nitric oxide visualized by micro-CT. *Am. J. Physiol. Renal Physiol.* Nov;285(5):F852-60.
68. Freytag, F.; Schelling, A.; Meinicke, T.; Deichsel, G. (2001): Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. *Clin. Ther.* Jan;23(1):108-123.
69. Fridman, K.U.; Elmfeldt, D.; Wysocki, M. Friberg, P.R. and Andersson, O.K. (2002): Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. *Blood Press.*;11(4):244-52.
70. Fujita, K.; Matsumura, Y.; Kita, S.; Miyazaki, Y.; Hisaki, K.; Takaoka, M. and Morimoto, S (1995): Role of endothelin-1 and ET_A receptor in maintenance of deoxycorticosterone acetate-salt induced hypertension. *Br. J. Pharmacol.* 114: 925-930.
71. Furukawa, R.F. and Bahdrakon, S. (1953): Reaction of strips of rabbit aorta to epinephrine isopropyl arterenol, sodium nitrate and other drugs. *J. Pharmacol. Exp. Ther.* 108: 129-143.
72. Furukawa, Y.; Kishimoto, S. and Nishikawa, K. (1982): Hypotensive imidazole-5-acetic acid derivatives. *Us. patent* 4,355,040. Issued to Takeda chemical Industries Ltd (Osaka, Japan).
73. Gainer JV, Morrow JD, Loveland A et al. (1998): Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. *N. Engl. J. Med.*; 339:1285-1292.
74. Garcha, R.S.; Sever, P.S. and Hughes, A.D. (1999): Action of AT₁ receptor antagonists on angiotensin II induced tone in human isolated subcutaneous resistance arteries. *Br. J. Pharmacol.* 127: 1876-1882.

-
75. Gavras, H.; Brunner, H.R.; Laragh, J.H.; Vaughn, E.D; Koss, M., Cote, L.J. and Gavras, I. (1975): Malignant hypertension resulting from DOCA and salt excess. *Circ. Res.*, 36: 300-309.
76. Gelband, C.H; Sumners, C.; Lu, D. and Raizada, M.K. (1997): Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. *Regul. Pept.* 72 (2-3): 139-45.
77. Gil-Extremera, B.; Ma, P.T.; Yulde, J.; Kalnins, U.; Harkin, N. and Williams L. (2003): The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. *Int. J. Clin. Pract.* Dec;57(10):861-6.
78. Gohlke, P.; Pees, C. and Unger, T. (1998): AT₂ receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependedent mechanism. *Hypertension* 31: 349-355.
79. Gohlke, P.; Weiss, S.; Jansen, A.; Wienen, W.; Stangier, J.; Rascher, W.; Culman, J. and Unger, T. (2001): AT₁ receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. *J. Pharmacol. Exp. Ther.* Jul;298(1):62-70.
80. Goldberg, M.R.; Tanaka, W. and Barchwsky, A. (1993): Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. *Hypertension* 21: 704-13.
81. Goldberg, M.R.; Dradstreet, T. E. and McWilliams, E.J. (1995): Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. *Hypertension* 25: 37-46.
82. Goldberg, M.R. de Mey, C. and Wroblewski, J. M. (1996): Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. *Clin. Pharmacol. Ther.* 59 (1): 72-82.
83. Goldstone, (1983): Understanding medical statistics. William Heiniman, medical book, limited. London.

84. **Griendling, K.K.; Tsuda, T.; Berk, B.C. and Alexander, R.W. (1989):** Angiotensin II stimulation of vascular smooth muscle. *J. Cardiovasc. Pharmacol.* 14 (Suppl 6): S27-S33
85. **Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D. and Alexander, R.W. (1994):** Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ. Res.*; 74:1141-1148.
86. **Grollman, A. (1975):** Experimental induction of hypertension. In experimental induction of diseases, part three Heart and circulation. Schrier, J. and Ecler, O. (ed) P.79. Springer-Verlag. New York. Berlin. Heidelberg.
87. **Gross, F. (1968):** The regulation of aldosterone secretion by the renin angiotensin system under various conditions. *Acta Endocrine (Copenh)*; Suppl 124:141.
88. **Hackenthal, E. (1990):** Morphology, physiology and molecular biology of renin secretion. *Physiol.Rev.*70: 1067.
89. **Hansen, J.L.; Servant, G.; Baranski, T.J.; Fujita, T.; Iiri, T.; Haunso, S. and Sheikh, S.P. (2000):** Functional reconstitution of the angiotensin II type 2 receptor and G_i activation. *Circ. Res.* 87: 753-759.
90. **Haywood, J.R.; Shaffer, R.A. and Fastenow, C. (1981):** Regional blood flow measurements with pulsed Doppler flowmeter in conscious rats. *Am. J. Physiol.* 241: H273-H278.
91. **Hernandez-Hernandez, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernandez, M.J. Armas-Padilla, M.C. and Cammarata, R. (2002):** Angiotensin II receptor antagonists role in arterial hypertension. *J. Hum. Hypertens.* Mar;16 Suppl 1: S93-9.
92. **Heuer, H.J.; Dilger, C.; Michael-Hepp, J, et al. (1998):** Influence of repeated oral doses of telmisartan on the clinical pharmacology of glibenclamide in healthy subjects [abstract no. 38]. *Eur. J. Clin. Pharmacol.* Aug; 54 (6): A 12.
93. **Hjorth, S.A.; Schambye, H.T.; Greenlee, W.J. and Schwartz, T.W. (1994):** Identification of peptide binding residues in the

- extracellular domains of the AT1 receptor. *J. Biol. Chem.* 269: 30953-30959.
94. **Hollenberg, N.K.; Fisher, N.D.L. and Price, D.A. (1998):** Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. *Hypertension* 32: 387-392
95. **Holmgren, A.; Pantev, E.; Erlinge, D. and Edvinsson L.(1998):** Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries. *J Cardiovasc. Pharmacol.*;32(4):662-4.
96. **Horvath, C.M. and Darnell, J.E. (1997):** The state of the STATs: Recent developments in the study of signal transduction to the nucleus. *Curr. Opin. Cell Biol.* 9: 233-239.
97. **Hropot, M.; Langer, K.H.; Wiemer, G.; Grotsch, H. and Linz W.(2003):** Angiotensin II subtype AT(1) receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. *Naunyn. Schmiedebergs Arch. Pharmacol.* 367(3):312-7.
98. **Huraux, C.; Makita, T.; Kurz, S.; Yamaguchi, K.; Szlam, F.; Tarpey, M.M.; Wilcox, J.N.; Harrison, D.G. and Levy JH. (1999):** Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. *Circulation.*;99:53-59.
99. **Hvistendahl, J.J.; Pedersen, T.S.; Djurhuus, J.C.; Pedersen, E.B. and Frokiaer, J. (2002):** Losartan attenuates renal vasoconstriction in response to acute unilateral ureteral occlusion in pigs. *Urol. Res.* Jul;30(3):169-77.
100. **Ibsen, H.; Lindholm, L.H.; Pedersen, O.L.; Dahlof, B. and Kjeldsen, S.(2003):** The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study *Ugeskr Laeger.* 27;165(5):456-9.
101. **Ibsen, H.; Lindholm, L.H.; Pedersen, O.L.; Dahlof, B.; Kjeldsen, S. (2003):**The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study *Ugeskr. Laeger.* 27;165(5):459-62.

102. **Inagami, T. (1995):** Recent progress in molecular and cell biological studies of angiotensin receptors. *Curr. Opin. Nephrol. Hypertens.* 4: 47-54.
103. **Ingino, C.; Farsang, C.; Laucevicius, A. and Bergovec, M. (2003):** An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. *J. Int. Med. Res.* Nov-Dec;31(6):561-74.
104. **Ishihata, A. and Endoh, M. (1993):** Pharmacological characteristics of the positive inotropic effect of angiotensin II in the rabbit ventricular myocardium. *Br. J. Pharmacol.* Apr;108(4):999-1005.
105. **Ishii M. (2004):** Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan. *Nippon. Rinsho.* Jan;62(1):193-202.
106. **Ivanova, O.V.; Fomicheva, O.A.; Sergakova, L.M.; Chernova, N.A.; Rogoza, A.N. and Karpov, I.u.A. (2002):** Angiotensin II Receptor Blocker Telmisartan: Effect on 24-Hour Blood Pressure Profile and Left Ventricular Hypertrophy in Patients With Hypertension. *Kardiologiya*; 42(2):45-9.
107. **Iwai, N. and Inagami, T. (1992)** Identification of two subtypes in the type I angiotensin II receptor. *FEBS Lett* 298: 257-260.
108. **Iwamoto, K.; Chen, C. and Kato, L. (1987):**Effect of urethane anaesthesia and age on organ blood flow in rats measured by hydrogen gas clearance method. *J. Pharmacobiodyn.*, 10 (6): 280- 289.
109. **Izumi, H.; Nakai, T.; Kano, S.; Hoshi, K. and Ichihara K.(1996):** Effects of BIBR-277, an angiotensin II type I receptor antagonist, on stunned myocardium in dogs. *Coron Artery Dis* Oct;7(10):775-9
110. **Jackson, E.K. (2001):** Renin and angiotensin. In Goodman and Gilman's. *The pharmacological basis of therapeutics.* Hardman J.G. et al. (eds.): 10th ed. New York, Me Graw-Hill pp 809-841.
111. **Jackson, E.; Branch, R.; Margolius, H. and Oates, J. (1985):** Physiological functions of renal prostaglandin, rennin, and

- Kallikrein systems. In, The kidney: Physiology and pathophysiology . (Seldin, D.W., and Giebisch, G.H., eds) Raven Press, Ltd., New York; pp. 613-644.
112. Jerkic, M.; Miloradovic, Z.; Jovovic, D.; Mihailovic-Stanojevic, N.; Elena, J.V. Nastic-Miric, D.; Grujic-Adanja, G. et al. (2004): Relative roles of endothelin-1 and angiotensin II in experimental post-ischaemic acute renal failure. *Nephrol. Dial. Transplant.* Jan;19(1):83-94.
113. Johnston, C.I. (1992): Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. *J. Hypertens.* 10: 513-26.
114. Johnston, C.I. (1995): Angiotensin receptor antagonists: focus on losartan. *Lancet*, 346: 1403-1407.
115. Kalus, J.S. and White, C.M. (2002): Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications. *Ann. Pharmacother.* Nov;36(11):1759-66.
116. Karam, H.; Clozel, J.P.; Bruneval, P.; Gonzalez, M. F. and Menacl, J. (1999): Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. *Hypertension*, 34: 673-678.
117. Karlocai, K. (2003): Effects of angiotensin receptor inhibitors on cardiovascular endpoints—current and future evidence. *Orv. Hetil.* May 4;144(18 Suppl 1):901-3.
118. Katholi, R.E. (1983): Renal nerves in pathogenesis of hypertension in experimental animals an humans. *Am. J. Physiol.* 245 (1): F1- 14.
119. Kedzierski, R.M. and Yanagisawa M. (2001): Endothelin system: the double-edged sword in health and disease. *Annu. Rev. Pharmacol. Toxicol.*; 41: 851–876.
120. Kim, S. and Iwao, H. (2000): Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. *Pharmacol. Rev.* 52: 11-34

121. Kjeldsen, S.E.; Dahlof, B.; Devereux, R.B.; Julius, S.; Aurup, P.; Edelman, J.; Beevers, G.; de Faire, U.; Fyhrquist, F. et al. (2003): Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 289(6):700-1; author reply 701.
122. Klein, I.H.; Ligtenberg, G.; Oey, P.L.; Koomans, H.A. and Blankestijn, P.J. (2003): Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. *J. Am. Soc. Nephrol.* Feb;14(2):425-30.
123. Koobi, P.; Kalliovalkama, J.; Jolma, P.; Rysa, J.; Ruskoaho, H.; Vuolteenaho, O.; Kahonen, M.; Tikkanen, I.; Fan, M.; Ylitalo, P. and Porsti I.(2003): AT1 Receptor Blockade Improves Vasorelaxation in Experimental Renal Failure. *Ann. Rheum. Dis.* 62(6):572-5.
124. Lacourciere, Y. (2002): A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. *J. Int. Med. Res.*; Jul-Aug;30(4):366-79
125. Laflamme, A.K.; Oster, L.; Cardinal, R. and de Champlain, J. (1998): Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetat-salt hypertension. *Can. J. Physiol. Pharmacol.* 76 (6): 665-675.
126. Leever, S.J.; Vanhaesebroek, B. and Waterfield, M.D. (1999): Signaling through phosphoinositide 3-kinases: The lipids take centre stage. *Curr. Opin. Cell Biol.* 11: 219-225.
127. Lee-Ym, L.; Peng, Y.Y.; Ding, Y.A. and Yen, M.H. (1997): losartan attenuate myocardial ischemia- induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. *Am. J. Hypertens.* 10 (8):852-8.
128. Lenz, O.; Schmid, B.; Kilter, H.; La Rosee, K.; Flesch, M.; Kuhn-Regnier, F.; Sudkamp, M. and Bohm M. (1995): Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium. *Eur. J. Pharmacol.* Dec 27;294(1):17-27.

129. Li, J.S.; Sharafi, A.M. and Schiffrin EL.(1997): Effect of AT1 angiotensin-receptor blockade on structure and function of small resistance arteries in SHR. *J. Cardiovasc. Pharmacol.*;30:75–83.
130. Lijnen, P.J.; Petrov, V.V.; Jackson, K.C. and Fagard RH. (2001): Effect of telmisartan on angiotensin II-mediated collagen gel contraction by adult rat cardiac fibroblasts. *J. Cardiovasc. Pharmacol.* Jul;38(1):39-48.
131. Linas, S.L. (1984): Role of prostaglandins in renin secretion in the isolated kidney. *Am. J. Physiol.* 246:F811-F818.
132. Lindpaintner, K. and Ganten (1991): The cardiac renin angiotensin system: an appraisal of present experimental and clinical evidence. *Circ. Res.*; 68: 905-921.
133. Linz, W. and Scholkens, B.A. (1992): A specific B₂ bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. *Br. J. Pharmacol.*;105:771–772.
134. Linz W, Wiemer G, Gohlke P, et al. (1995): Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. *Pharmacol. Rev.*; 47:25–49.
135. Littlejohn, T.; Mroczek, W.; Marbury, T.; VanderMaelen, C.P. and Dubiel, R.F. (2000): A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. *Can. J. Cardiol.* Sep;16(9):1123-32.
136. Liu, F.Y. and Cogan, M.G. (1987): Angiotensin II: a potent regular of acidification in the rat early proximal convoluted tubule. *J. Clin. Invest.* 80: 272-275.
137. Liu Y.S.; Shankley, N.P.; Welsh, N.J. and Black, J.W, (1992): Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action. *Br. J. Pharmacol.* 106: 233-241.
138. Liu, D.T.; Birchall, I.; Hewitson, T.; Kincaid-Smith, P. and Whitworth, J.A. (1994): Effect of dietary calcium on the development of hypertension and hypertensive vascular lesions in

- DOCA-salt and two kidney, one-clip hypertensive rats. *J. Hyperten.* 12: 145-153.
139. **Lo, M.W.; Goldberg, J.B. and Lu, H. et al. (1995):** Pharmacokinetics of losartan, an angiotensin II receptor antagonist. And its active metabolite E-3174 in humans. *Clin. Pharmacol. Ther.* 58 (6): 641-649.
140. **Lorenz, J.N.; Wwihprecht, H.; Schnermann, J.; Skott, O. and Briggs, J.P. (1991):** Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. *Am. J. Physiol.* 260: F486-F493.
141. **Ma, X.; Sigmund, C.D.; Hingtgen, S.D.; Tian, X.; Davisson, R.L.; Abboud, F.M. and Chapleau, M.W. (2004):** Ganglionic action of angiotensin contributes to sympathetic activity in renin-angiotensinogen transgenic mice. *Hypertension.* Feb;43(2):312-6.
142. **Mackay, J.H.; Arcuri, K.E. and Goldberg, A.I. et al. (1996):** Losartan and low dose hydrochlorothiazide in patients with essential hypertension. *Arch. Inter. Med.* 156: 278-285.
143. **Maeso, R.; Rodrigo, E.; Munoz-Garcia, R.; Navarro-Cid, J.; Ruilope, L.M.; Lahera, V. and Cachofeiro, V. (1997):** Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide. *J. Hypertens., Dec.; 15 (12pt.2):* 1677-84.
144. **Mahmud, A. and Feely, J. (2002):** Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. *Am. J. Hypertens.* Dec;15(12):1092-1095.
145. **Maillard, M.; Centeno, C.; Frostell-Karlsson, A.; Brunner, H.R. and Burnier, M. (2001):** Does protein binding modulate the effect of angiotensin II receptor antagonists? *JRAAS* 2: S54-S58.
146. **Maillard, M.P.; Perregaux, C.; Centeno, C.; Stangier, J.; Wienen, W.; Brunner, H.R. and Burnier, M. (2002):** In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. *J. Pharmacol. Exp. Ther.* Sep;302(3):1089-95

147. **Mallion, J.; Siche, J. and Lacourciere, Y. (1999):** ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. *J. Hum. Hypertens.* Oct;13(10):649-50.
148. **Manolis, A.J.; Reid, J.L.; de Zeeuw, D, et al. (2001):** Angiotensin II receptor antagonist ,micardis, in isolated systolic hypertension (ARMIS) study: Efficacy and safety of telmisartan 20, 40, or 80 mg versus hydrochlorothiazide or placebo [abstract no. P2. 154]. *J. Hypertens*, 19 Suppl. 2: S147.
149. **Marchand E.L.; Der Sarkissian, S.; Hamet, P. and deBlois D. (2003):** Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats. *Circ Res.* Apr 18;92 (7):777-84.
150. **Martinez,Y.; Martinez, S.; Meaney, A.; Meaney, E. and Escalante, B. (2002):** Angiotensin II type 1 receptor blockade restores nitric oxide-dependent renal vascular responses in renovascular hypertension. *J. Cardiovasc. Pharmacol.* Sep;40(3):381-7.
151. **Matsumura, Y.; Taira, S.; Kitano, R.; Hashimoto, N. and Toshihiko, K. (1999):** Selective antagonism of endothelin ET_A or ET_B receptor in renal hemodynamics and functions of deoxycorticosterone acetate-salt induced hypertensive rats. *Biol. Pharm. Bull.*, 22(8): 858-862.
152. **Mazzolai, L.; Maillard, M.; Rossat, J.; Nussberger, J.; Brunner, H.R. and Burnier, M. (1999):** Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists *Hypertension.* 33: 850-855.
153. **Merard, J. (1993):** Anthology of renin angiotensin system: a one hundred reference approach to Ang II antagonists. *Hypertension* 11 (suppl 3): S3-S11.
154. **Morgan, L.; Pipkin, F.B. and Kalsheker, N. (1996):** Angiotensinogen: Molecular biology, biochemistry and physiology. *Int. J. Biochem. Cell. Biol.* 28: 1211-1222.

155. **Moscyci, M.; Marcus, R. Korgarz, S. (1991):** Endogenous angiotensin II regulates ventricular contractility in vivo: a study using DuP 753, a novel angiotensin II receptor antagonist. Clin. Res.; 39: 693A.
156. **Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R.E. and Dzau, V.J. (1993):** Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268: 24539-24542.
157. **Mysnychenko, O,V. (2002):** Clinico-hematological effectiveness in losartan for treating hypertensive patients. Lik. Sprava.;(3-4): 117-20.
158. **Nahmias, C. and Strosberg, D. (1995):** The angiotensin AT receptor: Searching.. for signal-transduction pathways and physiological function. Trends. Pharmacol. Sci. 16: 223-225.
159. **Nakai, T.; Satoh, K.; Kosugi, T.; Hoshi, K. and Ichihara K. (1999):** Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium. Eur. J. Pharmacol. Oct 15;382(3):187-96.
160. **Nap, A.; Balt, J.C.; Pfaffendorf, M. and Van Zwieten, P.A. (2002):** Sympatholytic properties of several AT₁-receptor antagonists in the isolated rabbit thoracic aorta. J. Hypertens.;20(9):1821-8.
161. **Navar, L.G.; Harrison-Bernard, L.M. and Mitchell, K.D. (2000):** Renal responses to AT₁ receptor blockade. Am. J. Hypertens. 13: 45S-54S.
162. **Neutel , J.M., and Smith, D.H.G. (1998):** dose response and antihypertensive efficacy of the AT₁receptor antagonist telmisartan in patient with mild to moderate hypertension. Adv. Ther 15: 206-17.
163. **Neutel, J. and Smith, D.H. G. (2003):** Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J. Clin. Hypertens. (Greenwich). Jan-Feb;5(1):58-63.

164. Neutel, J.M.; Frishman, W.H.; Oparil, S.; Papademitriou, V. and Guthrie, G. (1999): Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. *Am J Ther* May;6(3):161-6.
165. Neutel, J.M.; Kolloch, R.E.; Plouin, P.F.; Meinicke, T.W.; Schumacher, H. OTELLOH Study Group. (2003): Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. *Hum. Hypertens.* Aug;17(8):569-75.
166. Nickenig, G.; K. Strehlow, J.; Roeling, O.; Zolk, A.; Knorr, and M. Böhm. (1998): Salt induces vascular AT1 receptor overexpression in vitro and in vivo. *Hypertension* 31: 1272-1277.
167. Nicoletti, A; Heudes, D. and Hinglas, N. (1995): Left ventricular fibrosis in renovascular hypertensive rats. *Hypertension* 26: 101-11.
168. Nussberger, J.; Cugno, M.; Amstutz, C. et al. (1998): Plasma bradykinin in angio-oedema. *Lancet.* 1998;351:1693-1697.
169. Oliveira, D.R.; Santos, R.A.; Santos, G.F.; Khosla, M. and Campagnole-Santos, M.J. (1996): Changes in baroreflex control of heart rate produced by central infusion of angiotensin antagonists in hypertensive rats. *Hypertension* 27 (6): 1284-1290.
170. Otsuka, K. and Tsukiyama, H. (1995): Hemodynamic effect of MK-954 (losartan potassium), an angiotensin II receptor antagonist, in patients with essential hypertension. *Rinsho. Lyaku.* 11 (1): 165-174.
171. Ozono, R.; Wang, Z.Q.; Moore, A.F.; Inagami, T.; Siragy, H.M. and Carey, R.M. (1997): Expression of the subtype 2 angiotensin (AT₂) receptor protein in rat kidney. *Hypertension* 30: 1238-1246.
172. Paget G.E and Barnes J.M.(1964): Evaluation of drug activities : Pharmacometrics. Volume 1; Toxicity tests, Chapter 6; P 135-166.
173. Panek, R.L.; Lu, G.H.; Overhiser, R.W.; Major, T.C.; Hodges, J.C. and Taylor, D.G. (1995): Functional studies but not

- receptor binding can distinguish surmountable from insurmountable AT1 antagonism. *J. Pharmacol. Exp. Ther.* 273: 753-761.
174. **Park, C.G. and Leenen, F.H. (2001):** Effects of centrally administered losartan on deoxycorticosterone-salt hypertensive rats. *J. Korean Med. Sci.* Oct., 16: (5): 553-557.
175. **Parker, A.B.; Azevedo, E.R.; Baird, M.G.; Smith, S.J.; Arnold, J.M.; Humen, D.P.; Moe, G.W.; Parker, J.O.; Butt, R.W. and Parker, J.D. (1999):** assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada.
176. **Phillips, M.I. and Sumners, C. (1998):** Angiotensin II in central nervous system physiology. *Regul. Pept.* 78: 1-11.
177. **Pietrement, C.; Malot, L.; Santerne, B.; Roussel, B.; Motte, J. and Morville, P. (2003):** Neonatal Acute Renal Failure Secondary to Maternal Exposure to Telmisartan, Angiotensin II Receptor Antagonist. *J. Perinatol.* May;23(3):254-5.
178. **Pitt, G.; Poole-Wilson, P.A.; Segal, R. et al. (ELITE II investigator) (2000):** effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. *Lancet* 355: 1582-1587.
179. **Podzolkov, V.I.; Bulatov, V.A.; Son, E.A. and Os, I. (2003):** Central and peripheral hemodynamic effects of losartan and in combination with hydrochlorothiazide in mild to moderate essential hypertension. *Blood Press.*; 12 (4):239-45.
180. **Pueyo, M.E.; Arnal, J.F.; Rami, J. and Michel, J.B. (1998):** Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. *Am. J. Physiol.* Jan;274(1Pt1):C214-20.
181. **Qadri, F.; Arens, T.; Schwarz, E.C.; Hauser, W.; Dendorfer, A. and Dominiak, P. (2003):** Brain nitric oxide synthase activity in spontaneously hypertensive rats during the development of hypertension. *J. Hypertens.* Sep;21(9):1687-94.

182. **Rhee, S.G. and Choi, K.D. (1992):** Regulation of inositol phospholipid-specific phospholipase C isozymes. *J. Biol. Chem.* 267:12393-12396.
183. **Richard, V.; Hogie, M. and Thuillez, C. (2002):** Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats. *Fundam. Clin. Pharmacol.*; 14: 101-106.
184. **Richer, C.; Domergue, V.; Vincent, M.P. and Giudicelli, J.F. (1996):** Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pitched spontaneously hypertensive rats. *Br.J. Pharmacol.* 117: 315-324.
185. **Rigol, M.; Heras, M.; Solanes, N.; Epelde, F.; Roig, E.; Perez-Villa, F.; Roque, M. and Sanz G. (2003):** Enalaprilat, losartan and LU 135252 in coronary blood flow regulation. *Eur. J. Clin. Invest.* 33(5):363-9.
186. **Rizzoni, D.; Porteri, E.; Castellano, M.; Bettoni, G.; Muiesan, M.L. Muiesan, P. Giulini, S.M.; Agabiti-Rosei, E. (1996):** Vascular hypertrophy and remodeling in secondary hypertension. *Hypertension.* Nov;28(5):785-90.
187. **Rizzoni, D.; Porteri, E.; Piccoli, A.; Castellano, M.; Bettoni, G.; Muiesan, M.L.; Pasini, G.; Guelfi, D.; Mulvany, M.J. and Rosei, E.A.(1998):** Effects of losartan and enalapril on small artery structure in hypertensive rats. *Hypertension.* ;32:305-31
188. **Robertson, M.J.; Dougall, I.G.; Harper, D.; McKechnie, K.C.W. and Leff, P. (1994):** Agonist-antagonist interactions at angiotensin-receptor: application of a two-state receptor model. *Trends Pharmacol. Sci.* 15: 364-369.
189. **Robinson, M.J. and Cobb, M.H. (1997):** Mitogen-activated protein kinase pathways. *Curr. Opin. Cell. Biol.* 9: 180-185.
190. **Ruddy, M.C.; Kostis, J.B. and Frishman, W.H. (1998):** Drugs that affect the renin angiotensin system. In :Cardiovascular pharmacotherapeutics. New York: Mc Graw-Hill. Renal consequences of hypertension. *J. Hypertens*;10(suppl7):S85-S90.

191. **Ruilope, L.M.; Alcázar, J.M. and Rodicio, J.L. (1992):** Renal consequences of hypertension. *J. Hypertens.*;10(suppl 7): S85-S90.
192. **Sadoshima, J. and Izumo, S. (1996):** The heterotrimeric Gq protein-coupled angiotensin II receptor activates p21ras via the tyrosine kinase Shc-Grb-Sos pathway in cardiac myocytes. *EMBO. J.* 15: 775-787.
193. **Samra, S.S.; Dongre, N.; Ballary, C. and Desai, A. (2003):** Comparison of the efficacy, safety and tolerability of telmisartan with losartan in Indian patients with mild to moderate hypertension: a pilot study. *J. Indian Med Assoc.* May;101(5):327-8.
194. **Sandberg, K. (1994):** Structural analysis and regulation of angiotensin II receptors. *Trends Endocrinol Metab.* 5: 28-35.
195. **Saris JJ, van Dijk MA, Kroon I, Schalekamp MA and Danser AH (2000):** Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. *Hypertension.* 35: 764-768.
196. **Sarkis, A.; Liu, K.L.; Lo, M.; Benzoni, D. (2003):** Angiotensin II and renal medullary blood flow in Lyon rats *Am. J. Physiol. Renal Physiol.* Feb;284(2):F365-72.
197. **Schaefer, A.; Lüker, P.W.; Brickel, M.; et al. (2001):** Pharmacokinetic evidence of a lack of interaction between telmisartan and simvastatin. Poster presented at the 4th International Symposium on Angiotensin II Antagonism. Apr. 3-5; London.
198. **Schiffrin, E.L. (1992):** Reactivity of small blood vessels in hypertension: relationship with structural changes. *Hypertension.* 2;19(supplII):II-1-II-9.
199. **Schiffrin, E.L. (2002):** Beyond blood pressure: the endothelium and atherosclerosis progression. *Am. J. Hypertens.* Oct;15 (10 Pt 2):115S-122S.

200. **Schiffrin, E.L. (2002):** Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers. : Can. J. Cardiol. May;18 Suppl A:15A-18A.
201. **Schiffrin, E.L. and Deng, L.Y. (1996):** Structure and function of resistance arteries of hypertensive patients treated with a β -blocker or a calcium channel antagonist. J. Hypertens.;14:1247-1255.
202. **Schiffrin, E.L. Park,J.B. Intengan, H. D. and Touyz R. M. (2000):** Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.Circulation;(101):1653.
203. **Scott, B.A.; Lawrence, B.; Nguyen, H.H. and Meyer, W.J. (1987):** Aldosterone and dexamethazone binding in human arterial smooth muscle cells. J. Hypertens. 5: 739-744.
204. **Sharpe, M.; Jarvis, B. and Goa, K.L. (2001):** Telmisartan: a review of its use in hypertension. Drugs ;61(10):1501-29.
205. **Shaw, W. and Snavely, D. (1994):** Safety and efficacy of losartan (DuP 753, MK 954) in hypertensive patients with renal impairment {abstract}. J. Am. Soc. Nephrol. 5: 567.
206. **Shelat, S.G.; King, J.L.; Flanagan-Cato, L.M. and Fluharty, S.J. (1999):** Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology. May, : 69 (5): 339-351.
207. **Shibasaki, Y.; Nishiue, T.; Masaki, H.; Matsubara, H. and Iwasaka T.(2002):** Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD) Nippon Rinsho. 60(10):1992-8.
208. **Shiota, N.; Okunishi, H.; Takai, S.; Mikoshiba, I.; Sakonjo, H.; Shibata, N. and Miyazaki, M. (1999):** Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation. 99: 1084-1090.
209. **Sielecki, A.R; Hayakawa, K; Fujinaga, M.E.; Fraser, M.; Muir, A.K.; Carilli, C.T.; Lewicki, J.A; Bxter, J.D. and James, M.N. (1989):** Structure of recombinant human renin, a target for

- cardiovascular-active drugs, at 2.5 Å resolution. *Science*. 243: 1346-1351.
210. **Siragy, H.M and Carey R.M. (1996):** The subtype-2 (AT₂) angiotensin receptor regulates renal cyclic guanosine 3',4'-monophosphate and AT₁ receptor-mediated prostaglandin E₂ production in conscious rats. *J. Clin. Invest.* 97: 1978-1982.
211. **Siragy, H.M. and Carey, R.M. (1997):** The subtype 2 (AT₂) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *J. Clin. Invest.* 100: 264-269.
212. **Siragy, H.M.; de Gasparo, M. and Carey, R.M. (2000):** Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. *Hypertension* 35: 1074-1077.
213. **Skeggs, L (1984):** Historical overview of the renin angiotensin system. In *hypertension and the angiotensin system : Therapeutic Approaches*. (Doyle A.E., and Bearn A. G., eds) Raven Press, New York, pp. 31-45.
214. **Smith, D.H. (2002):** Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. *Am. J. Hypertens.* Oct;15 (10 Pt 2):108S-114S.
215. **Smith, D.H.; Matzek, K.M. and Kempthorne-Rawson, J. (2000):** Dose response and safety of telmisartan in patients with mild to moderate hypertension. 82: *J. Clin. Pharmacol.* Dec;40 (12 Pt 1):1380-90.
216. **Smith, D.H.; Cramer, M.J.; Neutel, J.M.; Hettiarachchi, R. and Koval, S. (2003):** Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. *Blood Press Monit.* Jun;8(3):111-7.
217. **Smrcka, A.V.; Hepler, J.r.; Brown, K.O. and Sternweis, P.C. (1991):** Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq. *Science*. (Wash DC) 251: 804-807.
218. **Spence, J.D. (1995):** Cerebral consequences of hypertension. In: *Laragh JH, Brenner BM, eds. Hypertension, Pathophysiology,*

Diagnosis and Management. 2nd ed. New York, NY: Raven Press Publishers;: 741.

219. Stangier, J.; Schmid, J.; Turck, D.; Switek, H.; Verhagen, A.; Peeters, P.A.; van Marle, S.P.; Tamminga, W.J.; Sollie, F.A. and Jonkman, J.H. (2000): Absorption, metabolism, and excretion of intravenously and orally administered [^{14}C]telmisartan in healthy volunteers. *J. Clin. Pharmacol.* Dec;40 (12 Pt 1):1312-22.
220. Stangier, J.; Su, C.A.; Brickl, R. and Franke, H. (2000): Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. *J. Clin. Pharmacol.* Dec;40 (12 Pt 1):1365-72.
221. Stangier, J.; Su, C.A.; Fraunhofer, A. and Tetzloff, W. (2000): Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. *J. Clin. Pharmacol.* Dec;40(12 Pt 1):1338-46.
222. Stangier, J.; Su, C.A.; Hendriks, M.G.; van Lier, J.J.; Sollie, F.A.; Oosterhuis, B. and Jonkman, J.H. (2000): Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. *J. Clin. Pharmacol.* Dec;40(12 Pt 1):1331-7.
223. Stangier, J.; Su, C.A.; Hendriks, M.G.; van Lier, J.J.; Sollie, F.A.; Oosterhuis, B. and Jonkman, J.H. (2000): The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. *J. Clin. Pharmacol.* Dec;40 (12 Pt 1):1373-9.
224. Stangier J, Su CA, Schondorfer G, Roth W. (2000): Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. *J. Clin. Pharmacol.* Dec;40 (12 Pt 1):1355-64.
225. Stangier, J.; Su, C.A.; van Heiningen, P.N.; Meinicke, T.; van Lier, J.J.; de Bruin, H.; Tamminga, W.J. and Jonkman, J.H. (2001): Inhibitory effect of telmisartan on the blood pressure

- response to angiotensin II challenge. *J. Cardiovasc. Pharmacol.* Nov;38(5):672-85.
226. **Stapff, M.; Dueck, K.D. and Richard, F. (1995):** Evaluation of the antihypertensive efficacy of losartan, an angiotensin II antagonist, compared to captopril using 24h ABPM [Abstract]. Seventh European Meeting on Hypertension: 183.
227. **Storm, D.S. and Webb, R.C. (1992):** α -adrenergic receptors and $^{45}\text{Ca}^{2+}$ efflux in arteries from deoxycorticosterone acetate hypertensive rats. *Hypertension* 19: 734-738.
228. **Strehlow, K.; Nickenig, G.; Roeling, J.; Wassmann, S.; Zolk, O.; Knorr, A. and Böhm, M. (1999):** AT₁ receptor regulation in salt-sensitive hypertension *Am. J. Physiol. Heart Circ. Physiol.* 277: H1701-H1707.
229. **Strohmenger, H.U.; Lindner, K.H.; Wienen, W., and Vogt, J. (1997):** Effects of the AT₁-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. *Resuscitation.* Aug;35(1):61-8.
230. **Susman, V. (2003):** Cardiovascular Morbidity and Mortality in Hypertensive Patients With Atrial Fibrillation: The LIFE Study .Doctor's guide Abstract: 1133-147.
231. **Sylvester, B. (2003):** Efficacy and safety in patients with renal impairment treated with telmisartan (Esprit): An open-label multicentre study in patients with mild-to-moderate hypertension and mild-to-moderate or severe renal impairment or requiring maintenance dialysis. Doctors guide, June.
232. **Takahashi, S.; Moriwaki, Y.; Yamamoto, T.; Tsutsumi, Z.; Ka, T. and Fukuchi, M. (2003):** Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
233. **Takai, S.; Shiota, N.; Jin, D. and Miyazaki M (1998):** Functional role of chymase in angiotensin II formation in human vascular tissue. *J. Cardiovasc. Pharmacol.* 32: 826-833.
234. **Takezako, T.; Gogonea, C.; Saad, Y.; Noda, K. and Karnik, S.S. (2004):** Network leaning1 as a mechanism of insurmountable

- antagonism of the AT₁ receptor by non-peptide antagonists. *J. Biol. Chem.* 30 [Epub ahead of print].
235. Thybo, N.K.; Stephens, N.; Cooper, A.; Aalkjaer, C.; Heagerty, A.M. and Mulvany, M.J. (1995): Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. *Hypertension*;25(pt1):474-481.
236. Timmermans, P.B.; Wong, P.C.; Chiu, A.T. and Herblin, W.F. (1991): Nonpeptide angiotensin II receptor antagonists. *Trends Pharmacol. Sci.* 12: 55-61.
237. Timmermans, P.B.; Wong, P.C.; Chiu, A.T.; Herblin, W.F.; Benfield, P.; Carini, D.J.; Lee, R.J.; Wexler, R.R.; Saye, J.A. and Smith, R.D. (1993): Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol. Rev.*;45(2): 205-51.
238. Touyz, R.M. and Schiffrin, E.L. (2000): Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol. Rev.* 52: 639-672.
239. Touyz, R.M.; Deng, L.Y.; He, G. and Schiffrin, E.L. (1999a): Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human peripheral resistance arteries role of extracellular signal-regulated kinases. *J. Hypertens.* 17: 907-917.
240. Touyz, R.M.; Endemann, D.; He, G.; Li, J.S. and Schiffrin, E.L. (1999b): Role of AT₂ receptors in angiotensin II-stimulated contraction of small arteries in young SHR. *Hypertension* 33 (1 pt 2): 366-373.
241. Touyz, R.M.; He, G.; Deng, L. Y. and Schiffrin, E.L. (1999c) Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance vessels. *Circulation.* 99: 392-399.
242. Touyz, R.M.; El Mabrouk, M. and Schiffrin, E.L. (1999d): MEK inhibition attenuates Ang II-mediated signaling and contraction in SHR vascular smooth muscle cells. *Circ. Res.* 84: 505-515.

-
243. Tsutsumi, Y.; Matsubara, H.; Ohkubo, N.; Mori, Y.; Nozawa, Y.; Murasawa, S.; Kijima, K.; Maruyama, K.; Masaki, H.; Moriguchi, Y.; Shibasaki, Y.; Kamihata, H.; Inada, M.; Tsuzuki, S.; Eguchi, S. and Inagami, T. (1998): Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. *Circ. Res.* 83: 1035-1046.
244. Tsuzuki, S.; Eguchi, S. and Inagami T. (1996): Inhibition of cell proliferation and activation of protein tyrosine phosphatase mediated by angiotensin II type 2 (AT₂) receptor in R3T3 cells. *Biochem. Biophys. Res. Commun.* 228: 825-830.
245. Ueno, Y.; Mohara, O.; Brosnihan, K.B. and Ferrario, C.M. (1998): Characteristics of hormonal and neurogenic mechanisms of deoxycorticosterone acetate-induced hypertension. *Hypertension* 11 (Suppl.1): I 172-177.
246. Unger T. (2003): The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. *Am. J. Cardiol.* May 22;91(10A):28-34.
247. Unger, T. and Kaschina, E. (2003): Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives *Drug Saf.*;26(10):707-20.
248. Unger, T.; Badoer, E.; Ganten, D.; Lang, R.E. and Rettig, R. (1988): Brain angiotensin: pathways and pharmacology. *Circulation.* 77 (Suppl 1): I40-I54.
249. Urata, H.; Nishimura, H. and Ganten, D. (1996): Chymase-dependent angiotensin II forming systems in humans. *Am J Hypertens* 9: 277-284.
350. Ushio-Fukai, M.; Griendling, K.K.; Akers, M.; Lyons, P.R. and Alexander, R.W. (1998): Temporal dispersion of activation of phospholipase C-beta 1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. *J. Biol. Chem.* 273: 19772-19777.
251. Vanderheyden, P.M.L.; Fierens, F.L.P.; de Backer, J.P. and Vauquelin, G. (2000a): Reversible and syntopic interaction

- between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. *Biochem. Pharmacol.* 59: 927-935.
252. **Vanderheyden, P.M.L.; Fierens, F.L.P. and Vauquelin, G. (2000b):** Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition? *Biochem. Pharmacol.* 60: 1557-1563.
253. **Van Meel, J.C.; Redemann, N. and Haigh, R.M. (1996):** Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. *Arzneimittelforschung.* Aug;46(8):755-9.
254. **Vaziri, N.D.; Wang, X.Q.; Ni, Z.N.; Kivlighn, S. and Shahinfar, S. (2002):** Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. *Biochim. Biophys. Acta.* Oct 21;1592(2):153-61.
255. **Venema, R.C.; Ju, H.; Venema, V.J.; Schieffer, B.; Harp, J.B.; Ling, B.N.; Eaton, D.C. and Marrero, M.B. (1998):** Angiotensin II-induced association of phospholipase C gamma 1 with the G-protein-coupled AT1 receptor. *J.Biol. Chem.* 273: 7703-7708.
256. **Vingerhoedt, N.M.; Gilles, R.; Howes, J.B.; Griffin, M. and Howes, L.G. (2003):** Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers. *J. Renin Angiotensin Aldosterone Syst.* Dec;4(4):244-8.
257. **Wachtell, K.; Dahlof, B.; Rokkedal, J.; Papademetriou, V.; Nieminen, M.S.; Smith, G.; Gerds, E.; Boman, K.; Bella, J.N. and Devereux, R.B. (2003):** Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. *Am. Heart J.* 144(6):1057-64.
258. **Wada, T.; Kanagawa, R.; Yoshimasa, I. and Inada, Y. (1995):** Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. *J. Hypertens.* 13: 113-122.

259. **Wagner, J.; Drab, M.; Bohlender, J.; Amann, K.; Wienen, W. and Ganten, D. (1998):** Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. *Clin. Exp. Hypertens.* Feb;20(2):205-21.
260. **Watanabe, A. and Endoh, M. (1998):** Relationship between the increase in Ca^{2+} transient and contractile force induced by angiotensin II in aequorin-loaded rabbit ventricular myocardium. *Cardiovasc. Res.* Feb;37(2):524-31.
261. **Weber, K.T. (1997):** Extracellular matrix remodeling in heart failure; a role for de novo angiotensin II generation . *Circulation.* 96: 4065-4082.
262. **Weber, M.A.; Bynny, R.L. and Pratt, J.H. (1995):** Blood pressure effects of the angiotensin II receptor blocker, losartan. *Arch. Intern. Med.* 155:405-11.
263. **Wienen, W. and Entzeroth, M. (1994):** Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat. *J. Hypertens.* Feb;12(2):119-28.
264. **Wienen, W.; Mauz, A.B.M.; Van Meel, J.C.A. and Entzeroth, M. (1992):** Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. *Mol. Pharmacol* 41: 1081-1088.
265. **Wienen, W.; Huel, N.; Van Meel, J.C.; Narr, B.; Ries, U. and Entzeroth, M.(1993):** Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist BIBR 277. *Br. J.Pharmacol.*;110(1):24552.
266. **Wienen, W.; Entzeroth, M.; van Meel JCA, et al. (2000):** A review on telmisartan: a novel long acting angiotensin II receptor antagonist. *Cardiovasc. Drug Rev.* 18 (2): 127-56.
267. **Wienen, W.; Richard, S.; Champeroux, P. and Audeval-Gerard, C. (2001):** Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. *J. Renin Angiotensin Aldosterone Syst* Mar; 2(1):31-6.

-
268. Willenheimer, R.; Dahlöf, B. and Erhardt L. (1999): AT₁ receptor blockers in hypertension and heart failure: Clinical experience and future direction. *Eur. Heart. J.* 20: 997-1008.
269. Winkler, G.; Jermendy, G. and Matos, L. (2003): Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology. *Orv. Hetil.* Sep 7;144(36):1763-8.
270. Winquist, R.; Panzenbeck, M.; Madwed, J. et al. (1994): the effects of BIBR 277, an angiotensin II type I (AT₁) receptor antagonist in conscious monkeys [Abstract no. 5113]. *FASEBJ.* Mar. 18; 8 (5Pt II): A 882.
271. Wong, P.C.; Chiu, A.T.; Price, W.A. et al. (1988): Nonpeptide angiotensin II receptor antagonists, 1: Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307) *J. Pharmacol. Exp. Ther.*, 247: 1-7.
272. Wong, P.C.; Chiu, A.T. Price, W.A. et al. (1990): Nonpeptide angiotensin II receptor antagonist. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. *J. Pharmacol. Exp. Ther.* 252: 719-725.
273. Yamada, T.; Horiuchi, M. and Dzau, V.J. (1996): Angiotensin II type 2 receptor mediates programmed cell death. *Proc. Natl. Acad. Sci. USA* 93: 156-160.
274. Yamada, T.; Akishita, M.; Pollman, M.J.; Gibbons, G.H.; Dzau, V.J. and Horiuchi M (1998): Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: An in vivo gene transfer study. *Life Sci.* 63: 289-295.
275. Yang, E.K.; Lee, W.J.; Park, Y.Y.; Ahn, D.K.; Park, J.S. and Kim, H.J. (1996): Effect of chronic central administration of losartan on the cardiovascular and hormonal responses to hemorrhage in conscious rats. *Regul. Pept.* (67 (2): 107-113.
276. Yang, Y.J.; Tang, Y.D.; Ruan, Y.M.; Zhang, F.; Zhou, Y.W.; Wang, P.H.; Gao, R.L.; Chen, J.L. and Chen, Z.J. (2003): Comparative effects of carvedilol and losartan alone and in

combination for preventing left ventricular remodeling after acute myocardial infarction in rats. *Circ. J.* 67(2):159-62.

277. **Yongue, B.C.; Angulo, J.A.; McEwen, B.S. and Myers, M.M. (1991):** Brain and liver angiotensinogen messenger RNA in genetic hypertensive and normotensive rats. *Hypertension*, 17: 485-491.
278. **Young, C.L.; Dias, V.C. and Stangier, J. (2000):** Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. *J. Clin. Pharmacol.* Dec;40(12 Pt 1):1323-30.
279. **Ytterberg, H. and Edvinsson, L. (2001):** Characterisation of angiotensin II receptors in isolated human subcutaneous resistance arteries. *J. Renin-Angiotensin-Aldosterone System* 2: S37-S41.
280. **Yu, G.; Liang, X.; Xie, X.; Yang, T.; Sun, M. and Zhao S.(2002):** Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. *Chin. Med. J. (Engl)*.115(9):1287-91.
281. **Yusuf, S. (2002):** From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. *Am. J. Cardiol.* Jan 24;89(2A):18A-25A; discussion 25A-26A.
282. **Zhuo, J.; Moeller, I.; Jenkins, T.; Chai, S.Y.; Allen, A.M.; Mitsuru, O. and Mendelsohn, A.O. (1998):** Mapping tissue angiotensin-converting enzyme and angiotensin AT₁, AT₂ and AT₄ receptors. *J. Hypertens.* 16: 2027-2037.
283. **Zimmerman, J.B; Robertson, D. and Jackson, E.K. (1987):** Angiotensin II-noradrenergic interactions in renovascular hypertensive rats. *J. clin. Invest.* 80: 443-457.